Clinical Trial Detail

NCT ID NCT02224781
Title Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Ipilimumab + Nivolumab

Dabrafenib + Trametinib

Age Groups: adult

Additional content available in CKB BOOST